Expression and clinical significance of ASB6 in colorectal cancer tissues

doi:10.3760/cma.j.cn371439-20230523-00090

Abstract

Abstract: Objective To explore the expression and clinical significance of ASB6 in colorectal cancer tissue. Methods The cancer tissues and para-carcinoma tissues were selected from 106 patients with colorectal cancer admitted to the Department of Gastrointestinal Surgery， Third Affiliated Hospital of Shandong First Medical University from January 2015 to January 2018. Immunohistochemical method was used to detect the expression level of ASB6 protein in tissues， and the correlation between its expression and clinical pathological characteristics of patients was analyzed. At the same time， the expression of ASB6 mRNA in colorectal cancer tissues and para-carcinoma tissues was detected by quantitative real-time PCR （qRT-PCR）. The Kaplan-Meier survival analysis method was used to explore the relationship between the expression of ASB6 and prognosis in colorectal cancer patients. The Cox regression model was used to analyze the independent prognostic factors of colorectal cancer patients. Results The high expression rate of ASB6 in colorectal cancer tissues （67.9%， 72/106） was significantly higher than that in para-carcinoma tissues （10.4%，11/106， χ²=73.67， P<0.001）. Further analysis showed that the expression of ASB6 protein was significantly correlated with lymph node metastasis （χ²=7.34， P=0.007） and TNM stage （χ²=16.85， P<0.001）. There was no significant correlation between the expression of ASB6 protein and age （χ²=0.42， P=0.516）， sex （χ²=0.76， P=0.385）， tumor size （χ²=0.91， P=0.341）， tumor location （χ²=2.29， P=0.130）， histological classification （χ²<0.01， P>0.999）， differentiation degree （χ²=2.54， P=0.111） and distant metastasis （χ²=3.38， P=0.066）. qRT-PCR results showed that the expression level of ASB6 mRNA in colorectal cancer tissues was significantly higher than that in para-carcinoma tissues （5.37±0.13 vs. 3.39±0.09， t=-12.48， P<0.001）. Kaplan-Meier survival analysis showed that the overall 5-year survival rates of patients in the ASB6 high expression group （72 cases） and the ASB6 low expression group （34 cases） were 45.8% and 73.5%， respectively （χ²=6.82， P=0.009）. Univariate survival analysis found that ASB6 protein expression （HR=3.09， 95%CI： 1.25-7.65， P=0.015）， lymph node metastasis （HR=0.41， 95%CI： 0.21-0.82， P=0.011）， distant metastasis （HR=0.20， 95%CI： 0.10-0.42， P<0.001）， and TNM stage （HR=0.10， 95%CI： 0.03-0.32， P<0.001） were prognostic factors， while multivariate Cox survival analysis found that distant metastasis （HR=0.22， 95%CI： 0.09-0.50，P<0.001） and TNM stage （HR=0.25， 95%CI： 0.11-0.58， P<0.001） were independent prognostic factors. Conclusion The expression of ASB6 in colorectal cancer tissues is significantly higher than that in para-carcinoma tissues， and the prognosis of patients with high expression of ASB6 is significantly worse than that of patients with low expression of ASB6. ASB6 can be used as an important indicator for early monitoring and postoperative survival assessment of colorectal cancer patients in the future.

Key words: Colorectal neoplasms, ASB6, Prognosis

Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.

Figures/Tables 4

References 10

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	Zhao H, Ming T, Tang S, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target[J]. Mol Cancer, 2022, 21(1): 144. DOI: 10.1186/s12943-022-01616-7. pmid: 35836256
[3]	Wilcox A, Katsanakis KD, Bheda F, et al. Asb6, an adipocyte-specific ankyrin and SOCS box protein, interacts with APS to enable recruitment of elongins B and C to the insulin receptor signaling complex[J]. J Biol Chem, 2004, 279(37): 38881-38888. DOI: 10.1074/jbc.M406101200. pmid: 15231829
[4]	Hung KF, Lai KC, Liu TY, et al. Asb6 upregulation by Areca nut extracts is associated with betel quid-induced oral carcinogenesis[J]. Oral Oncol, 2009, 45(6): 543-548. DOI: 10.1016/j.oralonco-logy.2008.10.004.
[5]	Hung KF, Liao PC, Chen CK, et al. ASB6 promotes the stemness properties and sustains metastatic potential of oral squamous cell carcinoma cells by attenuating ER stress[J]. Int J Biol Sci, 2019, 15(5): 1080-1090. DOI: 10.7150/ijbs.31484.
[6]	Zhang J, Zhou YJ, Yu ZH, et al. Identification of core genes and clinical roles in pregnancy-associated breast cancer based on integrated analysis of different microarray profile datasets[J]. Biosci Rep, 2019, 39(6): BSR20190019. DOI: 10.1042/BSR20190019.
[7]	Gong L, Wang K, Wang M, et al. CUL5-ASB6 complex promotes p62/SQSTM1 ubiquitination and degradation to regulate cell proli-feration and autophagy[J]. Front Cell Dev Biol, 2021, 9: 684885. DOI: 10.3389/fcell.2021.684885.
[8]	Bretthauer M, Løberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death[J]. N Engl J Med, 2022, 387(17): 1547-1556. DOI: 10.1056/NEJMoa2208375.
[9]	Zeng W, Zhu JF, Guo J, et al. m⁶A-modified circFNDC3B inhibits colorectal cancer stemness and metastasis via RNF41-dependent ASB6 degradation[J]. Cell Death Dis, 2022, 13(11): 1008. DOI: 10.1038/s41419-022-05451-y. pmid: 36446779
[10]	Xiong L, Liu HS, Zhou C, et al. A novel protein encoded by circINSIG1 reprograms cholesterol metabolism by promoting the ubiquitin-dependent degradation of INSIG1 in colorectal cancer[J]. Mol Cancer, 2023, 22(1): 72. DOI: 10.1186/s12943-023-01773-3. pmid: 37087475

临床病理特征	例数	ASB6表达		χ²值	P值
临床病理特征	例数	高表达（n=72）	低表达（n=34）	χ²值	P值
年龄（岁）
<60	64	45（70.3）	19（29.7）	0.42	0.516
≥60	42	27（64.3）	15（35.7）	0.42	0.516
性别
男	59	38（64.4）	21（35.6）	0.76	0.385
女	47	34（72.3）	13（27.7）	0.76	0.385
肿块大小（cm）
<5	49	31（63.3）	18（36.7）	0.91	0.341
≥5	57	41（71.9）	16（28.1）	0.91	0.341
肿瘤位置
结肠	39	30（76.9）	9（23.1）	2.29	0.130
直肠	67	42（62.7）	25（37.3）	2.29	0.130
淋巴结转移
有	45	37（82.2）	8（17.8）	7.34	0.007
无	61	35（57.4）	26（42.6）	7.34	0.007
远处转移
有	14	13（92.9）	1（7.1）	3.38	0.066
无	92	59（64.1）	33（35.9）	3.38	0.066
组织学类型
腺癌	95	65（68.4）	30（31.6）	<0.01	>0.999
黏液腺癌	11	7（63.6）	4（36.4）	<0.01	>0.999
分化程度
中分化	79	57（72.2）	22（27.8）	2.54	0.111
低分化	27	15（55.6）	12（44.4）	2.54	0.111
TNM分期
Ⅰ期	10	2（20.0）	8（80.0）	16.85	<0.001
Ⅱ期	46	29（63.0）	17（37.0）
Ⅲ期	38	33（86.8）	5（13.2）
Ⅳ期	12	8（66.7）	4（33.3）

因素	单因素分析			多因素分析
因素	HR值	95%CI	P值	HR值	95%CI	P值
年龄	0.73	0.36~1.49	0.391
性别	0.57	0.28~1.17	0.127
肿块大小	0.78	0.40~1.52	0.464
肿瘤位置	0.62	0.32~1.20	0.157
淋巴结转移	0.41	0.21~0.82	0.011	1.98	0.87~4.50	0.104
远处转移	0.20	0.10~0.42	<0.001	0.22	0.09~0.50	<0.001
组织学类型	1.78	0.69~4.59	0.235
分化程度	1.42	0.68~2.95	0.352
TNM分期	0.10	0.03~0.32	<0.001	0.25	0.11~0.58	<0.001
ASB6表达	3.09	1.25~7.65	0.015	2.05	0.90~4.67	0.086

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[7]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[8]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[9]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[10]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[11]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[12]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[13]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[14]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[15]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.